Skip to content

Head to head

Efinopegdutide against Semaglutide

A GLP-1 and glucagon dual agonist against a GLP-1 agonist, tested directly on liver fat rather than on weight. This pair is here because the result separates the two things that usually travel together in this drug class: the liver effect was far larger while the weight difference was not significant, which is what isolates the glucagon contribution.

Column A

Efinopegdutide

Efinopegdutide (MK-6024), GLP-1 and glucagon receptor dual agonist

Beat semaglutide on liver fat in a randomised head to head, cutting it 72.7 percent against 42.3 percent, while the weight difference was not significant. Adding glucagon does something to the liver that GLP-1 alone does not.

Column B

Semaglutide

Semaglutide (GLP-1 receptor agonist)

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.

These two were tested against each other directly

A head to head trial, not two separate records compared by us.

Liver fat content fell 72.7 percent (90% CI 66.8 to 78.7) on efinopegdutide against 42.3 percent (90% CI 36.5 to 48.1) on semaglutide, p < 0.001. Body weight fell 8.5 percent against 7.1 percent, p = 0.085, which is not significant. Adverse events were slightly higher on efinopegdutide, primarily gastrointestinal.

What the trial was

Phase IIa, randomised, active-comparator-controlled, parallel-group, open-label. 145 participants with non-alcoholic fatty liver disease and liver fat content of 10 percent or more on MRI, randomised 1:1 to efinopegdutide 10 mg or semaglutide 1 mg weekly for 24 weeks, both titrated over eight weeks, stratified by type 2 diabetes status. Primary endpoint was relative reduction in liver fat content at week 24. Mean baseline BMI 34.3 and liver fat 20.3 percent; 33.1 percent had type 2 diabetes.

What the authors concluded

The authors state that efinopegdutide led to a significantly greater reduction in liver fat content than semaglutide. They attribute it to glucagon receptor agonism acting on the liver directly to stimulate fatty acid oxidation and reduce lipogenesis, in addition to the indirect effect of weight loss.

Where this result is weak

The comparator dose is the thing to notice. Semaglutide 1 mg is a type 2 diabetes dose, well below the 2.4 mg approved for obesity, so this is not a comparison against semaglutide at its strongest. The trial was open-label, which matters less for an MRI-measured endpoint than for a reported one. And liver fat content is a biomarker: it predicts risk and it is not fibrosis, cirrhosis or death, none of which 145 people over 24 weeks could measure.

Phase IIa active-comparator study (NCT04944992), Journal of Hepatology, 2023

Side by side, on the facts we can check

AttributeEfinopegdutideSemaglutide
CategoryMetabolicMetabolic
FDA statusInvestigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers.FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management)
Half-lifeLong-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded.~7 days
Molecular weightPeptide conjugated to a long-acting carrier. No mass asserted; no source loaded states one.4,113.6 Da
MechanismA co-agonist at the GLP-1 and glucagon receptors, built on a long-acting Fc-based scaffold. GLP-1 receptor agonism reduces food intake and improves glycaemic control in the usual way. Glucagon receptor agonism raises hepatic fatty acid oxidation and reduces de novo lipogenesis, and also increases energy expenditure, which is the intended mechanism for the liver fat effect. The glycaemic risk of glucagon agonism is the reason these drugs are balanced rather than glucagon-dominant.Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake.
Human studies cited35
Legal status, USInvestigational, not approvedFDA-approved, prescription only
open the Efinopegdutide profileopen the Semaglutide profile

Frequently asked questions

What is the difference between Efinopegdutide and Semaglutide?

Efinopegdutide: Beat semaglutide on liver fat in a randomised head to head, cutting it 72.7 percent against 42.3 percent, while the weight difference was not significant. Adding glucagon does something to the liver that GLP-1 alone does not. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.

Which has stronger research evidence, Efinopegdutide or Semaglutide?

This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Efinopegdutide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are Efinopegdutide and Semaglutide FDA-approved?

Efinopegdutide: Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers.. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).

Related posts

Blog articles that cover Efinopegdutide or Semaglutide, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.